Chief Executive Officer
Anders has a broad financial and entrepreneurial background and has successfully been structuring and developing new ventures in various branches. He also has experience from leading positions as CEO, CFO and board member in both private and listed companies.
Anders joined Isofol Medical AB in 2010.
Position: Chief Executive Officer
Year of birth: 1970
Holdings*: 115 932 shares
*Own or related natural or legal person holding shares and other financial instruments in the company. Holdings as of 3rd of September.View Profile
Chief Medical Officer
Karin Ganlöv is accountable for medical advice and medical decisions related to the development of arfolitixorin (Modufolin®). She is also the company’s personal data protection representative/officer and is responsible for the clinical research team. Karin is a medical doctor (MD) from Lund University. She is specialized/board certified in cardiothoracic surgery and has research experience from the field of inflammatory diseases. The last 13 years she has worked in the pharmaceutical and medical device industry, initially as a medical advisor within her field of expertise, and the last 8 years as Medical Director, of which the last 5 years was in a role with corporate and global responsibility.
Karin joined Isofol Medical AB in April 2015.
Position: Chief Medical Officer
Year of birth: 1964
Holdings*:13 664 shares
Phone:(+46)702 433 750
*Own or related natural or legal person holding shares and other financial instruments in the company. Holdings as of 1th of March.View Profile
Chief Commercial Officer
Sven Ericksson lead the licensing and commercialization efforts of the company’s lead candidate arfolitixorin (Modufolin®). Prior to joining Isofol, Mr. Erickson served as Director of Medical Affairs in the Nordic region at PTC Therapeutics. Preceding his employment at PTC Therapeutics was his role as Product Search and Evaluation Manager at Medivir, a research-based pharmaceutical company with focus on oncology, managing in-licensing operations. Before joining Medivir in 2014, Mr. Erickson have also held different positions at Novartis including Scandinavian Medical Head of Critical Care. Mr. Eriksson has a PhD in Experimental Oncology from The Karolinska Institute, Sweden.
Sven joined Isofol Medical AB in August 2017.
Position: Chief Commercial Officer
*Own or related natural or legal person holding shares and other financial instruments in the company. Holdings as of 15th of May.
Chief Financial Officer
Gustaf is a business-oriented economist with broad financial and operational experience. He is responsible for the company’s financial management and reporting and will play an important role in the company’s continued efforts to develop its investor relations. Gustaf comes must recently from the position of CEO of Elanders Sverige AB, a subsidiary of Elanders AB, listed on Nasdaq Stockholm’s Mid Cap list, and was before that the CFO for the same company. Prior to Elanders, Gustaf worked for Deloitte and Arthur Andersen as an accountant for 17 years and as an authorized accountant for 11 years. During his time as auditor, Gustaf gained broad and profound knowledge in accounting and financial reporting, focusing on IFRS, for larger Swedish and international companies. Gustaf holds a Master of Science in Economics and International Accounting and Auditing from the School of Economics from the University of Gothenburg.
Gustaf joined Isofol Medical AB in November 2017.
Position: Chief Financial Officer
Holdings*: 8 000 shares and 0 warrants
Phone: +(46) 709 168 302